> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Fast Tracks Invectys IVS-3001
- URL: https://www.fdaweb.com/fda-fast-tracks-invectys-ivs-3001/
- Published: 2023-08-01T12:00:00.000Z
- Updated: 2026-09-14T18:47:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155000

FDA has granted fast-track designation to Invectys’ IVS-3001 for treating renal cell cancer. A company [statement](https://www.invectys.com/news/fda-grants-fast-track-designation-to-ivs-3001-invectys-car-t-cell-therapy-in-the-treatment-of-renal-cell-carcinoma/?ref=fdaweb.com) says the designation was based on data from an IND submission and the potential for meeting the unmet needs of patients with HLA-G positive locally advanced or metastatic clear cell renal cell carcinoma who have failed or are intolerant to standard renal cell carcinoma therapies.

The company says IVS-3001 is a cutting-edge CAR-T cell immunotherapy that targets the rarely exploited immune checkpoint and tumor-specific antigen HLA-G. The antigen can be used by tumors, Invectys says, to create a protective microenvironment, evading the immune system and promoting tumor growth. “By targeting this mechanism,” it says, “IVS-3001 aims to reinvigorate the body’s natural defense to combat cancer effectively.”